ArticleStem cell reviews and reports2010
Human embryonic stem cell-extracts inhibit the differentiation and function of monocyte-derived dendritic cells.
Article in Stem cell reviews and reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Flavonoids in Combination with Stem Cells for the Treatment of Neurological Disorders.Neurochemical research · 2023Review
- Co-treatment with grape seed extract and mesenchymal stem cells in vivo regenerated beta cells of islets of Langerhans in pancreas of type I-induced diabetic rats.Stem cell research & therapy · 2022Article
- Stem Cell Therapy for Thyroid Diseases: Progress and Challenges.Current therapeutic research, clinical and experimental · 2022Review
- Stem cell transplantation therapy for diabetic foot ulcer: a narrative review.Asian biomedicine : research, reviews and news · 2021Review
- Addressing Stem Cell Therapeutic Approaches in Pathobiology of Diabetes and Its Complications.Journal of diabetes research · 2018Review
- Current Perspective of Stem Cell Therapy in Neurodegenerative and Metabolic Diseases.Molecular neurobiology · 2017Review
- Inherent Immunogenicity or Lack Thereof of Pluripotent Stem Cells: Implications for Cell Replacement Therapy.Frontiers in immunology · 2017Review
- Cancer Immune Equilibrium and Schizophrenia Have Similar Interferon-γ, Tumor Necrosis Factor-α, and Interleukin Expression: A Tumor Model of Schizophrenia.Schizophrenia bulletin · 2016Article
- Stem Cells and Lung Regeneration.International journal of stem cells · 2016Review
- MFG-E8 Is Critical for Embryonic Stem Cell-Mediated T Cell Immunomodulation.Stem cell reports · 2015Article
- Induced pluripotent stem cells have similar immunogenic and more potent immunomodulatory properties compared with bone marrow-derived stromal cells in vitro.Regenerative medicine · 2014Article
- Immunogenicity and tumorigenicity of pluripotent stem cells and their derivatives: genetic and epigenetic perspectives.Current stem cell research & therapy · 2014Review
- Pluripotent stem cells: immune to the immune system?Science translational medicine · 2012Review
- Embryonic stem cell-derived factors inhibit T effector activation and induce T regulatory cells by suppressing PKC-θ activation.PloS one · 2012Article
- Immunological applications of stem cells in type 1 diabetes.Endocrine reviews · 2011Review
- Risk factors in the development of stem cell therapy.Journal of translational medicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Embryonic stem cells (ESC) possess inherent properties of immune privilege with the capacity to evade allogeneic immune responses. Moreover, ESCs have been shown to prevent immune activation in response to third party antigen presenting cells in vitro and have the capacity to promote allograft survival in vivo. However, clinical use of human ESCs to treat immunological disorders may risk teratoma or ectopic tissue formation. Here, we show that cellular extracts from both human and mouse ESCs retain the immune modulatory properties of intact cells. ESC-extracts that contained 12-24 μg of total protein effectively prevented T cell proliferation in allogeneic mixed lymphocyte reactions (MLR), whereas control fibroblast extracts did not affect proliferation. Cellular mechanisms underlying hESC extract-mediated immune modulation involve the maturation of monocyte derived dendritic cells (mDC). hESC extract-treated mDCs had reduced surface expression of co-stimulatory and maturation markers CD80, HLA-DR and CD83 and secreted lower levels of IL12p40. Accordingly, hESC extract-treated DCs were found to be poor stimulators of purified allogeneic T cells compared to those DCs treated with vehicle or fibroblast extracts. Our results demonstrate that ESC extracts retain the immune modulatory properties of ESCs and for the first time demonstrates that ESC derived factors can inhibit human mDC maturation and function.
Indexed as
Identifiers
20711689What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.